Adicet Bio (LTS:0HX7) Shareholder Yield % : 3.30% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
31 GF Score
Price $8.66
GF Value $0.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Shareholder Yield %?

Adicet Bio LTS:0HX7 +0.12% 31 Shareholder Yield % is 3.30% as of Mar. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 31/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,296 Biotechnology companies, Adicet Bio ranks better than 86.88% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Adicet Bio's Shareholder Yield % was 3.30%.


Adicet Bio  (LTS:0HX7) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Adicet Bio Shareholder Yield % Related Terms


Adicet Bio Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Shareholder Yield % Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial -34.14 -11.45 -0.96 -135.14 -89.18

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.84 7.31 5.16 -89.18 4.31

LTS:0HX7 vs ATRA, PYPD, GANX: Shareholder Yield % Comparison

For the Biotechnology subindustry, Adicet Bio's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Shareholder Yield % falls into.


LTS:0HX7
31GF Score
Adicet Bio Inc LTS:0HX7
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Shareholder Yield % Calculation

Adicet Bio's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+4.37 %
=4.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 3.30% mean?
Adicet Bio (LTS:0HX7) has a Shareholder Yield % of 3.30% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #170 out of 1296 companies in the Biotechnology industry, placing it in the top 13.1%.
Is Adicet Bio's Shareholder Yield % too high?
Adicet Bio's current Shareholder Yield % is 3.30%. Based on the distribution chart, Adicet Bio ranks #170 out of 1296 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adicet Bio has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Shareholder Yield % compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #170 out of 1296 companies for Shareholder Yield %. This places Adicet Bio in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Adicet Bio and its competitors. Adicet Bio's current Shareholder Yield % is 3.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $8.66 — trading 1868.2% above its estimated fair value. The current Shareholder Yield % is 3.30%. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Shareholder Yield % is 3.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adicet Bio (LTS:0HX7) Overvalued in 2026?

Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued. The current stock price of $8.66 is trading 1868.2% above its estimated GF Value™ of $0.44. GuruFocus considers Adicet Bio to be Significantly Overvalued.

Key valuation signals for LTS:0HX7:

  • Shareholder Yield %: 3.30%
  • GF Value™: $0.44 vs. price of $8.66 (1868.2% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for LTS:0HX7

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.66
Price
$0.44
GF Value